ServicesOur WorkInsightsFAQ
M Search · Healthcare Technology Intelligence Report

Health Tech
Sales Leadership
Compensation Benchmark

What it costs to hire a health tech sales leader — and why the segment you sell into changes everything.

Primary data from a live retained CRO search, not a compensation survey.

Comp by level·Seven health tech sales segments·Deal economics + cycles·What moves candidates
M SearchHealth Tech — Sales Leadership Comp Benchmark
About This Data

This benchmark is built from primary data collected during a live, retained executive search — not a compensation survey or a third-party dataset. The engagement was a US Chief Revenue Officer search for a UK-headquartered health technology company expanding into the US market.

As it scaled its US operation, the company was selling across the full breadth of the market — from behavioral-health and senior-living providers and the mid-market up through enterprise hospital systems — which required a commercial leader fluent across several distinct healthcare buyers. That breadth is what makes the resulting candidate pool an unusually complete cross-section of the US health tech sales leadership market. All figures below are aggregated; no individual or company is identified.

Shape of the Dataset
StageVolumeDetail
Sourced & evaluated~290US health tech sales-leadership candidates
Formally screened / interviewed~40By the M Search team; source of the comp + motivation data
Advanced to clientShortlistPresented for client interviews
Placed1US CRO
Table of Contents
Executive SummaryThe Shape of the Market
Section ICompensation by Level
Section IIThe Seven Segments of Health Tech Sales
Section IIIDeal Economics by Segment
Section IVWhat Moves These Candidates
Section VThe Platform-Incumbent Question
Section VIWhat the Data Means When You're Hiring
msearchco.com2
M SearchHealth Tech — Sales Leadership Comp Benchmark
Executive Summary

The Shape of the Market

US health tech sales leadership compensation is tightly clustered and predictable at the headline level. What is not obvious — and what a compensation survey cannot tell you — is that “health tech sales” is not one market but at least seven, each with a distinct buyer, sales cycle, and deal size. Matching the leader to the right segment is the single biggest predictor of a successful hire.

Six Numbers That Define It
$200–250K
Base-salary cluster for a US health tech VP Sales; $200K is a hard floor
~40 screened leaders
$350–500K
VP Sales OTE range — roughly 2× base on a 50/50 split
Aggregated candidate data
0.25–0.75%
Typical equity participation at the leadership level — ranked above cash
Aggregated candidate data
7
Distinct health tech sales markets — buyer, cycle, and deal size all differ
M Search segment analysis
$3K–$50M
Deal-size spread across segments — four orders of magnitude
Aggregated candidate data
~290
US health tech sales leaders sourced and evaluated for one search
M Search search data, 2025
Three Things the Data Makes Clear
01
Equity decides, not base
Base is commoditized at this level. The strongest candidates weigh equity and a credible 3–5 year exit story above cash.
02
Segment is destiny
An enterprise health-systems closer and a high-velocity clinics seller are different athletes. Mis-matching the two is the most common failure mode.
03
Candidates screen you on Epic defensibility
Provider-facing candidates will ask whether the product withstands platform incumbents nudging into their space before they commit.
msearchco.com3
M SearchHealth Tech — Sales Leadership Comp Benchmark
Section I

Compensation by Level

Ranges below are drawn from roughly 40 leadership candidates who disclosed current or target compensation during the search.

LevelBaseOTENotes
VP Sales (US head / first leader)$200K–$250K$350K–$500KThe center of gravity; $200K is a hard base floor
Director / first-line leader$150K–$200K$300K–$400KOften carries a quota slice
SVP / CRO / CCO$250K–$300K+$450K–$600KFull commercial P&L; equity is the lever
Compensation Ranges by Level (US, 2025–2026)
Base clusters $200–250K · OTE runs ~2× base on a 50/50 split
Director / First-Line Leader
Base$150K–$200K
OTE$300K–$400K
VP Sales (US Head / First Leader)
Base$200K–$250K
OTE$350K–$500K
SVP / CRO / CCO
Base$250K–$300K
OTE$450K–$600K
$0$150K$300K$450K$600K
M Search · US healthcare-technology CRO search · ~40 screened leadership candidates, 2025
The structure that clears the market
On a 50/50 split, OTE at roughly 2× base is the near-universal structure at this level — and equity, not base, is the lever that actually closes the candidate.

Equity, observed: participation typically negotiated in the ~0.25%–0.75% range, scaling with scope and stage. A minority of candidates discount early-stage equity given the low odds of a liquidity event, but the clear majority rank it as their #1 decision driver — above cash. Given 12–18 month enterprise cycles, a first-year ramp or guarantee is expected, not exceptional.

msearchco.com4
M SearchHealth Tech — Sales Leadership Comp Benchmark
Section II

The Seven Segments of Health Tech Sales

This is the intelligence a compensation survey cannot provide. Deal size, cycle length, buyer, and even who ultimately pays change sharply by segment. A leader who excels in one is frequently a mis-hire in another.

SegmentPrimary buyerDeal (ACV)Cycle
1 · Revenue cycle (RCM)Rev-cycle leaders, CFO$30K → $3M6–12 mo
2 · ClinicalCMO, CMIO, CNO$180K–$750K12–18 mo
3 · Benefits / employer wellnessCHRO, CFO via brokersVaries3–9 mo
4 · Pharma / life sciencesPharma / biotech pays$500K–$35M6–18 mo
5 · PayerHealth plans$100K–$400K+6–18 mo
6 · Health systems (enterprise)CIO, CMIO, CFO, CMO, CNO$180K–$50M12 mo–3 yr+
7 · Clinics (SMB, incl. behavioral)Practice / clinic execs$3K–$80K3 wks–6 mo

Benefits / wellness is a channel motion: sold through benefit consultants and brokers, not direct — the broker relationship is the moat.

In pharma / life sciences the money flips: pharma and biotech pay; health systems are execution partners, not the customer.

In enterprise health systems, IT is now a gatekeeper: platform-integration teams sit on the buying committee alongside clinical and financial leaders.

A company selling across the full spectrum — behavioral clinics and the mid-market through to enterprise systems — needs a leader who has genuinely operated on both ends. That cross-spectrum operator is rare and commands a premium, but the alternative is a leader who is fluent in one segment and lost in the next.
msearchco.com5
M SearchHealth Tech — Sales Leadership Comp Benchmark
Section III

Deal Economics by Segment

The spread is the story. Deal size ranges across four orders of magnitude, and cycle length from a few weeks to several years. A comp plan, quota, and ramp built for one segment will misfire in another.

Typical Deal Size (ACV) by Segment
From a $3K solo-practice sale to $50M enterprise — four orders of magnitude (log scale)
Clinics — SMB / behavioral$3K–$80K
Payer$100K–$400K
Benefits / employer wellness$50K–$500K
Clinical$180K–$750K
Revenue cycle (RCM)$30K–$3M
Pharma / life sciences$500K–$35M
Health systems — enterprise$180K–$50M
$10K$100K$1M$10M
M Search · US healthcare-technology CRO search · aggregated candidate deal data, 2025
Sales-Cycle Length by Segment
Weeks in the clinics/SMB lane; multiple years at the enterprise health-system end
Clinics — SMB / behavioral3 wks–6 mo
Benefits / employer wellness3–9 mo
Revenue cycle (RCM)6–12 mo
Payer6–18 mo
Pharma / life sciences6–18 mo
Clinical12–18 mo
Health systems — enterprise12 mo–3 yr+
09 mo18 mo27 mo36 mo
Why this matters for a quota
A velocity seller closing $25K behavioral-clinic deals in a month and an enterprise closer working a $50M health-system deal over three years cannot run on the same quota, comp plan, or ramp schedule. Set the number to the segment — not to a blended company-wide average.
msearchco.com6
M SearchHealth Tech — Sales Leadership Comp Benchmark
Section IV

What Moves These Candidates

Ranked by frequency across the screened population. Read together, they say the same thing: at this level the decision is about upside, mission, and trust in the plan — not the base number.

1.

Equity over base

Near-universal at VP and above. The recurring language: “meaningful equity,” “real upside,” “a clear light at the end of the tunnel.” Many will trade base for a larger stake at the right stage.
2.

A credible 3–5 year path to exit

Candidates explicitly frame the job as a multi-year grind toward a windfall. Backer quality and a clean cap table are gating — several cited being burned by dilution or cap-table control in the past.
3.

Patient-outcomes mission

Genuinely load-bearing in healthcare specifically — a real motivator, not a talking point, and a differentiator versus other software verticals.
4.

Builder identity and culture

Strong preference for zero-to-one scrappiness over inheriting a mature machine, and low tolerance for bureaucratic or “poisonous” cultures.
5.

Comp-plan integrity

A leading departure trigger is capped commissions, mid-year plan changes, or perpetually deferred recaps and payouts. The stability and fairness of the plan retain leaders as much as its headline number.
msearchco.com7
M SearchHealth Tech — Sales Leadership Comp Benchmark
Section V

The Platform-Incumbent Question

The single most-repeated competitive signal in the population is the platform incumbent — the dominant electronic-health-record systems — encroaching on point-solution territory. Candidates independently described incumbents offering their most profitable modules “basically free,” compressing digital-health valuation multiples from roughly 12× toward 5–6× on a multi-year horizon.

It's a candidate question, not a company screen
The practical implication is candidate-side. Strong provider-facing candidates will ask about it in the interview. They want confidence that the product genuinely withstands the platform nudging into adjacent workflows before they will commit their next 3–5 years.

Companies with a crisp, credible “why we win” answer — real integration, or non-overlapping value such as compliance, quality, oncology-specific, or revenue-cycle workflows — convert these candidates. Those without one lose them at diligence. If a provider-facing product cannot articulate its defensibility against the platform incumbent, that gap will surface in hiring long before it surfaces in the market.

The read for a hiring team
Have the defensibility narrative ready before you go to market for the leader. The best candidates treat it as a gating question — and the quality of your answer is, to them, a signal about the quality of the business.
msearchco.com8
M SearchHealth Tech — Sales Leadership Comp Benchmark
Section VI

What the Data Means When You're Hiring

1.

Lead with the cap table and the exit thesis, not base

Base is commoditized at this level. Equity and a credible 3–5 year story are what win the candidate — open with them.
2.

Hire to the segment, not to “healthcare”

Define whether the seat is enterprise-systems, clinics/velocity, RCM, payer, pharma, benefits, or clinical — and match the operator's proven segment. Cross-spectrum sellers are worth paying up for.
3.

Have a crisp “why we win” answer ready

Provider-facing candidates will ask about the platform incumbent, and it is a gating question for their commitment.
4.

Read scope, not titles

A health tech “VP” or “RVP” frequently maps to a senior individual contributor, not a people manager — unlike other software sectors. Benchmark on team built, quota owned, and P&L touched.
5.

Move fast

Strong finalists run two to four processes simultaneously; offer windows compress to two to three weeks once a leader is identified.
About M Search

M Search is a boutique executive search firm specializing in GTM and sales leadership mandates for PE-backed and VC-backed B2B software companies.

We run CRO, CMO, VP Sales, VP Marketing, and Customer Success searches for companies at the growth and transformation stage, with particular depth in healthcare technology and cross-border US expansion. This benchmark reflects proprietary data from a live 2025 US health tech CRO search, shared as market intelligence without attribution to any individual or company.

Talk to M Search →

Graham Locklear · M Search · graham@msearchco.com · linkedin.com/in/graham-locklear/

msearchco.com9